Calif. State Senator Vows to Push Life-Sci
Bill Without More Stem-Cell Amendments
By Alex Philippidis,
BioRegion News
| 07. 21. 2008
[Quotes CGS's Jesse Reynolds]
The California state Senator who authored a governance and drug-access bill opposed by the state's stem-cell agency told BioRegion News last week she didn't see the need for further amendments beyond those that have enabled the measure to clear a key Assembly committee and advance to the full Assembly.
State Sen. Sheila Kuehl (D-Santa Monica) said the amended bill would survive what she said were attempts by the California Institute for Regenerative Medicine to amend Senate Bill 1565 to death. Last week the stem-cell agency and a patients' rights group told BRN they would continue to fight the legislation because the changes didn't go as far as they had hoped, and because they fear it will discourage the funding of human embryonic stem cell research in the state.
In an interview, Kuehl said she would continue up to a point the dialogue with CIRM and its chairman, Robert Klein, that resulted in the amendments.
see more
"I always talk to people who want to talk to me, but it doesn't mean that we're going to continue to amend, and amend, and amend...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...